# Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects

> **NCT01324843** · PHASE1 · COMPLETED · sponsor: **National Institute on Aging (NIA)** · enrollment: 24 (estimated)

## Conditions studied

- Intradermal Electroporation

## Interventions

- **DRUG:** EMLA Cream
- **DRUG:** Aveeno Daily Moist
- **DEVICE:** Derma Vax
- **PROCEDURE:** Intradermal Electroporation
- **PROCEDURE:** Visual Analogue Scale
- **PROCEDURE:** Present Pain Intensity
- **PROCEDURE:** McGill Pain Questionnaire
- **PROCEDURE:** Skin Assessment

## Key facts

- **NCT ID:** NCT01324843
- **Lead sponsor:** National Institute on Aging (NIA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-25
- **Primary completion:** 2010-05-27
- **Final completion:** 2010-05-27
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324843, "Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01324843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*